Table 1.
Demographics and baseline characteristics
| ll patients, N=63,678 | n (%) |
|---|---|
| Age cohort, years | |
| 65–69 | 5,424 (8.5) |
| 70–74 | 7,688 (12.1) |
| 75–79 | 10,731 (16.9) |
| 80–84 | 14,212 (22.3) |
| ≥85 | 25,623 (40.2) |
| Sex | |
| Female | 39,008 (61.3) |
| Male | 24,670 (38.7) |
| Race/ethnicity | |
| White | 55,962 (87.9) |
| Black | 5,422 (8.5) |
| Hispanic | 999 (1.6) |
| Other | 1,295 (2.1) |
| Population density | |
| Urban | 45,453 (71.4) |
| Rural | 18,042 (28.3) |
| Unknown | 183 (0.3) |
| US geographic region | |
| Northeast | 13,437 (21.1) |
| Midwest | 16,522 (25.9) |
| South | 25,395 (39.9) |
| West | 8,168 (12.8) |
| Patients enrolled in Medicare Part D (n=35,788) | |
| Comorbidities | |
| Diabetes | 10,391 (29.0) |
| Hypertension | 23,111 (64.6) |
| Stroke | 346 (1.0) |
| Atrial fibrillation | 7,737 (21.6) |
| Myocardial infarction | 790 (2.2) |
| Drug exposurea | |
| β-Blockers | 21,036 (58.8) |
| HF-specific β-blockers | 16,335 (45.6) |
| ACEIs | 12,254 (34.2) |
| ARBs | 6,356 (17.8) |
| Diuretics | 22,295 (62.3) |
| Aldosterone antagonists | 2,344 (6.6) |
| Digitalis/inotropes | 5,130 (14.3) |
Note:
a
Rate per 100 person-years.
Abbreviations: HF, heart failure; ACEIs, angiotensin converting enzyme inhibitors; ARBs angiotensin receptor blockers.